Dear Participants of the 14th EAVPT Congress,

On behalf of the organizers of the 14th International Congress of EAVPT, it is my greatest pleasure to welcome you in Wroclaw. We did our best to develop a programme of the highest scientific level and with outstanding speakers – world-class specialists in veterinary pharmacology and toxicology as well as other related disciplines. Thanks to the Executive Committee, especially prof. Pierre-Louis Toutain and prof. Johanna Fink-Gremmels, I can proudly say that we have achieved this goal.

Herewith, I am giving into your hands the Congress programme. Together with the book of abstracts – the supplement to the Journal of Veterinary Pharmacology and Therapeutics – it should serve you well as a guide to the Congress events.

The main objective of the Congress is to exchange scientific ideas and learn about the latest research in the field of veterinary pharmacology and toxicology. While designing the programme, we have tried our best to satisfy the different tastes and interests of the participants. Based on the tradition of the previous Congresses, it is organized in a system of three parallel scientific sessions. It requires each of you to choose the individual path through the programme. We tried to minimize possible competition between sessions to facilitate the choice for participants of different interests.

I would like to underline that this year’s Congress coincides with the 40th anniversary of the EAVPT. This special moment requires special celebration, therefore on Monday evening (June 25th), I would like to invite you to the magnificent Wroclaw City Hall where prof. Peter Lees will give a speech and a short presentation of our EAVPT “family photos”.

I am sure that you will spend the time of the Congress in the most satisfying and beneficial manner. In situations requiring advice or help my team and I are at your disposal. Numerous volunteers (many of which are students of the Wroclaw Faculty of Veterinary Medicine) will be happy to provide you with assistance.

I do hope that your stay in Wroclaw will be a fruitful experience both in terms of intellectual as well as social events.

Yours sincerely,

prof. Marcin Świtała
**EXECUTIVE COMMITTEE**

**Chairman:** Marcin Świtała  
**Secretary:** Błażej Poźniak  
**Members:**  
Pierre-Louis Toutain, EAVPT President  
Johanna Fink-Gremmels, EAVPT Senior Vice President  
Lloyd Reeve-Johnson, EAVPT Junior Vice President  
Wolfgang Bäumer, EAVPT Secretary  
Maria Rosa Martinez-Larrañaga, EAVPT Treasurer  
Jean-Claude Desfontis, Organizer 13th EAVPT Congress  
Philippe Gruet, ECVPT President  
Jonathan Elliott, ECVPT Vice President

**LOCAL ORGANIZING COMMITTEE**

**Chairman:** Marcin Świtała  
**Vice-chairman:** Piotr Okoniewski  
**Secretary:** Błażej Poźniak  
**Members:** Tomasz Grabowski, Marta Tikhomirov, Krystyna Okoniewska

**ORGANIZERS OF PRECONGRESS WORKSHOPS**

**VetCAST workshop 1:** Determination of clinical breakpoints – Ludovic Pelligand,  
**VetCAST workshop 2:** Modelling and simulation – Ronette Gehring  
**Workshop on ThothPro software for pharmacokinetic analysis** – ThothPro Team  
**ECVPT Workshop:** Providing evidence of efficacy of veterinary medicinal products – Klaus Hellmann, Philippe Gruet

**ORGANIZERS OF SATELLITE CONFERENCES**

**Conference for Poultry Practitioners** – Alina Wieliczko  
**Conference for Ruminant Practitioners** – Jan Twardoń

**SCIENTIFIC COMMITTEE**

Getu Abraham (DE)  
Arturo Anadón (ES)  
Alain Bousquet-Mélou (FR)  
Wolfgang Baeumer (DE)  
George Batzias (GR)  
Clare Bryant (UK)  
Patrick De Backer (BE)  
Jérôme del Castillo (CA)  
Siska Croubels (BE)  
Mauro Dacasto (IT)  
Jonathan Elliot (UK)  
Carl Eckstrand (SV)  
Aude Ferran (FR)  
Johanna Fink-Gremmels (NL)  
Christian Friis (DK)  
Ronette Gehring (NL)  
Mario Giorgi (IT)  
Tomasz Grabowski (PL)  
Philippe Gruet (FR)  
Luca Guardabassi (DK)  
Klaus Hellmann (DE)  
Linda Horspool (UK)  
Jerzy Jaroszewski (PL)  
Manfred Kietzmann (DE)  
Jonathan King (CH)  
Carlos Lanusse (AR)  
Lubomir Lashev (BG)  
Peter Lees (UK)  
Maria-Aránzazu Martínez (ES)  
Marilyn Martinez (USA)  
Maria Rosa Martinez-Larrañaga (ES)  
Aneliya Milanova (BG)  
Paul Mills (AU)  
Jonathan Mochel (USA)  
Carlo Nebbia (IT)  
Bożena Obmińska-Mrukowicz (PL)  
Lena Olsen (SV)  
Ludovic Pelligand (UK)  
Mathieu Peyrou (CZ)  
Lucie Pokludová (CZ)  
Giovanni Re (IT)  
Jim Riviere (USA)  
Lloyd Reeve-Johnson (AU)  
Bertha São Braz (PT)  
Pascal Sanders (FR)  
Alejandro Soraci (AR)  
Stefan Soback (IS)  
Marcin Świtała (PL)  
Pierre-Louis Toutain (UK)  
Arno Werners (GD)  
Ted Whittem (AU)  
Zonghui Yuan (CN)
**Day 1: Sunday, 24th June**

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Room B</th>
<th>Room C</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:30</td>
<td>Opening ceremony</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:30</td>
<td>Opening plenary lectures</td>
<td>Prof. Pierre-Louis Toutain</td>
<td>Prof. Johanna Fink-Gremmels</td>
</tr>
<tr>
<td>20:00</td>
<td>Get-together party (Congress venue)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td>Special show of Wroclaw fountain (Congress venue)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Day 2: Monday, 25th June**

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Room B</th>
<th>Room C</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:30</td>
<td>Session 1 One Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 9:30</td>
<td>Session 2 Antimicrobials Susceptibility Testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 - 10:00</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 11:30</td>
<td>Plenary Lectures</td>
<td>Prof. Waleria Hryniewicz</td>
<td>Prof. Malcolm Rowland</td>
</tr>
<tr>
<td>11:30 -12:00</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 -13:30</td>
<td>Session 4 Drug Residues &amp; Food Safety</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:30</td>
<td>Session 7 Regulatory Affairs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>Roundtable discussion on regulatory issues</td>
<td>Poster session 1</td>
<td>Poster session 2</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>EAVPT general assembly</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td>Panoramic tour of Wroclaw</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td>Celebration of the 40th Anniversary of EAVPT (Old Town Hall)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Centennial Hall/Hala Stulecia (Congress Venue) is situated 2.9 km from the Old Town Market Square/City Center.

How to get from Wroclaw City Center to Centennial Hall (Congress venue)
Trams: 2, 4, 10 direction Biskupin/Sepolno (Centennial Hall/Hala Stulecia tram stop)
Bus: 115, 145, 146, 701 (Centennial Hall/Hala Stulecia bus stop)

Public transport route planner:
To plan your journey with public transport please visit:
http://komunikacja.iwroclaw.pl/?lang=pl&language=en or www.jakdojade.pl

---

Taxi corporations:
Partner Taxi tel. +48 519 119 627
e-mail: bok@tas-pol.pl
Radio Taxi Serc tel. +48 71 363 37 37
Miejskie Taxi tel. +48 787 088 099
Lux Radio tel. +48 601 902 323
I Taxi Wroclaw tel.+ 48 737 737 737
Centennial Hall is a unique venue on the map of Poland, where history harmoniously interacts with modernity. It was designed by Max Berg, an outstanding city architect, and recognized as one of the top masterpieces of the 20th century architecture. The designer assumed that the Hall was to serve citizens of Wrocław and visitors to Lower Silesia’s capital city, and it continues to perform this function successfully. Multi-purpose space, unusual structure, unique and spacious location represent just a few of its strengths.

Centennial Hall complex currently is one of the most desired venues among domestic and foreign organizers of major exhibitions, conferences, cultural, sport and congress events. The Hall’s inscription on UNESCO World Heritage List in 2006 emphasized the rank of this facility. Undoubtedly it is one of the most characteristic flagships of Wrocław in the international scale, and exceptionally magic site in the city where the charts of history record its multi-generational experience.
Social Events

Get-together party with special show of Wrocław fountain
Centennial Hall Wrocław Congress Center
(Congress Venue)
Address: Wystawowa 1
Sunday 24 June 20:00 – 22:00
*Included in the registration fee*

EVENING EAVPT 40TH ANNIVERSARY (Monday 25 June 18:15 -20:30)
Panoramic tour of Wrocław
Pick-up place: Congress venue
the tour ends with the celebration of the 40th Anniversary of EAVPT at the City Hall

Cocktail in the City Hall
Address: Rynek 50
*Included in the registration fee*

The Old City Hall's long history reflects developments that have taken place in the city since its initial construction. The town hall serves the city of Wrocław and is used for civic and cultural events such as concerts held in its Great Hall. The host of the cocktail will be the mayor of the city.

Gala dinner at the Topacz Castle
Address: Główna 12, Ślęza
Tuesday 26 June 20:00 – 24:00
Pick up from Centennial Hall at 19:30
Drop off – hotels Wrocław City Center
(1st coach leaving at 22:30)

Gala dinner will be held in Topacz Castle, a picturesque fourteenth century manor. We believe this will be a splendid event to close the second day of the Congress. Located in Lower Silesia (15 km out of Wrocław city centre), this newly renovated facility is a perfect combination of an old castle atmosphere and modern luxury. The Gala dinner will give you the opportunity to taste the delicacies of Polish cuisine and fresh local products from Lower Silesia – a region widely recognized for high-quality ecological farming. To turn our Gala dinner into a vivid and unforgettable event, we have invited a talented cover band Volare. We believe that their energetic performance and brilliant arrangements will leave very little space on the dancing floor! We will be honoured to meet with you there on Tuesday evening, June 26th!

Tickets for the Gala dinner will be available at the registration desk on 25 and 26 June.
Price: 60 EUR/per person (served dishes, buffet, beverages, 2 glasses of wine)

EAVPT 2018 Detailed programme

Day 1: Sunday, 24th June

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-21:00</td>
<td>Registration desk</td>
<td>Registration of participants</td>
</tr>
<tr>
<td>15:00</td>
<td>Auditorium</td>
<td>Opening ceremony of the 14th EAVPT Congress</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Opening plenary lectures</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairpersons: Marcin Świtala, Błażej Poźniak</td>
</tr>
<tr>
<td>15:30</td>
<td>Auditorium</td>
<td>PL.1 Veterinary pharmacotherapy: trends and expectations for the future</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PIERRE-LOUIS TOUTAIN</td>
</tr>
<tr>
<td>16:00</td>
<td>Auditorium</td>
<td>PL.2 One Health – challenges for the veterinary profession</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JOHANNA FINK-GREMMEL</td>
</tr>
<tr>
<td>20:00</td>
<td>Get-together party</td>
<td>Special show of Wrocław fountain</td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Day 2: Monday, 25th June

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-9:30</td>
<td>Auditorium</td>
<td>Parallel session 1: ONE HEALTH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairpersons: Lloyd Reeve-Johnson, Erwin Hohn, Jonathan Mochel, Błażej Poźniak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O1.1 KN The determinants of successful Global One Health Initiatives (complexity economics, game theory and medical perspectives) Lloyd Reeve-Johnson</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O1.2 KN Language, veterinary context and paradigmal considerations to leverage multidisciplinary collaboration. Erwin Hohn</td>
</tr>
<tr>
<td>Time</td>
<td>Room / Venue</td>
<td>Details</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>8:00-9:30</td>
<td>Room B</td>
<td><strong>Parallel session 2: ANTIMICROBIAL SUSCEPTIBILITY TESTING</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Pierre-Louis Toutain, Ludovic Pelligand, Piotr Okoniewski</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-9:30</td>
<td>Room C</td>
<td><strong>Parallel session 3: TOXICOLOGY 1</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Arturo Anadon, Laura N. Vandenberg, Marcin Świtalla</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-9:30</td>
<td>Room B</td>
<td><strong>Parallel session 2: ANTIMICROBIAL SUSCEPTIBILITY TESTING</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Pierre-Louis Toutain, Ludovic Pelligand, Piotr Okoniewski</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-9:30</td>
<td>Room C</td>
<td><strong>Parallel session 3: TOXICOLOGY 1</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Arturo Anadon, Laura N. Vandenberg, Marcin Świtalla</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30-10:00</td>
<td>Room C</td>
<td><strong>Parallel session 4: DRUG RESIDUES AND FOOD SAFETY</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Ronette Gehring, Andrea Barbarossa, Tomasz Grabowski</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30-10:00</td>
<td>Room C</td>
<td><strong>Parallel session 4: DRUG RESIDUES AND FOOD SAFETY</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Ronette Gehring, Andrea Barbarossa, Tomasz Grabowski</td>
</tr>
<tr>
<td>Time</td>
<td>Room / Venue</td>
<td>Details</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Room B</td>
<td>Parallel session 5: <strong>ANTIMICROBIALS - FARM ANIMALS 1</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alain Bousquet-Melou, Tae-Won Kim, Jerzy Jaroszewski</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O5.1 KN</strong> Precision medicine for the prudent use of veterinary antimicrobials in food producing animals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALAIN BOUSQUET-MÉLOU</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O5.2 KN</strong> Antibiotic treatments via drinking water in sheep fattening houses: how to ensure an adequate exposure of the treated population?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BÉATRICE B. ROQUES, MARLÈNE Z. LACROIX, LAURA FOUZARI, AUDE A. FERRAN, DIDIER CONCORDET &amp; ALAIN BOUSQUET-MÉLOU</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O5.3 KN</strong> Pharmacokinetics and pharmacodynamics of lincomycin and colistin combination in chickens</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NA-HYE PARK, SEUNG-JIN LEE &amp; SEUNG-CHUN PARK</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O5.4 KN</strong> Absorption of doxycycline from the gastrointestinal tract of broiler chickens after combined administration with feed and/or calcium, magnesium and iron compounds</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HANNA MADEJ-ŚMIECHOWSKA, HUBERT ZIÓŁKOWSKI &amp; JERZY J. JAROSZEWSKI</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O5.5 KN</strong> Post-antibiotic effect of danofloxacin in combination with ceftiofur and colistin on multidrug resistant Escherichia coli strains isolated from animals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MURAT CENGIZ, PINAR SAHI NTURK, GULCE HEPBOSTANÇI, SONGUL SONAL &amp; HALİS AKALİN</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Room C</td>
<td>Parallel session 6: <strong>ADVANCES IN ANTICANCER THERAPY</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aleksandra Pawlak, Mery Giantin</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O6.1 KN</strong> Personalized medicine in companion animals – selected issues</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALEKSANDRA PAWLAK</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O6.2 KN</strong> Targeting Canine KIT Promoter by a Candidate DNA G-quadruplex Ligand</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ELEONORA ZORZAN, SILVIA DA ROS, RAMY ELGENDY, MERY GIANTIN, LARA ZORRO SHAHIDIAN, CLAUDIA SISSI &amp; MAURO DACASTO</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O6.3 KN</strong> Radiotherapy plus temozolomide have no evident effect on the transcriptome landscape of canine malignant oral melanoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RAMY ELGENDY, LAURA MARCONATO, MERY GIANTIN, LUCA ARESU, PAOLA LAGANGA, MARTA VASCELLARI, VITO FERDINANDO LEONE, FRANCO MUTINELLI, MAURO DACASTO &amp; ANNA GRANATO</td>
</tr>
</tbody>
</table>

**EAVPT 2018 Detailed programme**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>Auditorium</td>
<td>Parallel session 7: <strong>REGULATORY AFFAIRS</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marilyn N. Martinez, Lucie Pokludová, Małgorzata Olejnik</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O7.1 KN</strong> Looking ahead – exploring alternative ways to answering clinical pharmacology questions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MARILYN N. MARTINEZ</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O7.2 KN</strong> Challenges associated with antimicrobial resistance for scientists and regulators considering new European Action Plan and future legislation on veterinary medicinal products</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LUCIE POKLUDOVÁ</td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>Room B</td>
<td>Parallel session 8: <strong>ANTIMICROBIALS - FARM ANIMALS 2</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peter Lees, Jérôme R. E. Del Castillo, Hubert Ziółkowski</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O8.1 KN</strong> Impact of bovine respiratory disease on the pharmacokinetics of danofloxacin and tulathromycin in different ages of calves</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DANIELLE A. MZYK, CLAIRE M. BUBLITZ, MARILYN N. MARTINEZ, JENNIFER L. DAVIS, RONALD E. BAYNES &amp; GEOF W. SMITH</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O8.2 KN</strong> Pharmacokinetics of tulathromycin in healthy goats and goats with induced Pasteurella multocida pneumonia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JOSEPH SMITH, JONATHAN P. MOCHLE, DAVID BORTS &amp; RONALD GRIFFITH</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O8.3 KN</strong> Epidemiologic and pharmacodynamic cutoff values of tilmicosin against Haemophilus parasuis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HAIHONG HAO, PENG ZHANG, JUN LI, GUYUE CHENG, DONGMEI CHEN, YANFEI TAO, LINGLI HUANG, YULIAN WANG, MENGHONG DAI, ZHENLI LIU &amp; ZONGHUI YUAN</td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>Room C</td>
<td>Parallel session 9: <strong>TOXICOLOGY 2</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Juliette Legier, Arturo Anadón, Marta Tikhomirov</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O9.1 KN</strong> Neonicotinoid Toxicity: overview including societal issues</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ARTURO ANADÓN</td>
</tr>
</tbody>
</table>
## Day 3: Tuesday, 26th June

### Parallel Session 10: Anaesthesia & Pain Control

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-9:30</td>
<td>Auditorium</td>
<td>Parallel session 10: Anaesthesia &amp; Pain Control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairpersons: Paulo Steagall, Lisbeth Olsen, Marcin Świtała</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O10.1 Novel analgesic strategies in feline pain management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PAULO STEAGALL</td>
</tr>
</tbody>
</table>

### Poster Session 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-17:00</td>
<td>Room B</td>
<td>Poster session 1 (Chairperson: Jérôme R. E. Del Castillo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sections:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P1 Antibiotics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P2 Antiparasitics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P3 Probiotics</td>
</tr>
</tbody>
</table>

### Poster Session 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Room C</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-17:00</td>
<td>Poster session 2 (Chairperson: Johanna Fink-Gremmels)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sections:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P4 Toxicology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P5 Contaminants</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P6 Anticancer drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P7 One Health &amp; translational medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P8 Advances in new veterinary drug formulation</td>
</tr>
</tbody>
</table>

### Roundtable Discussion on Regulatory Issues

15:30-16:00 Coffee break

**Moderators:** Johan Schefferle, Marilyn N. Martinez, Lucie Pokludová

16:00-17:00 Roundtable discussion on regulatory issues

**Chairpersons:** Aude A. Ferran, Eran Lavy, Alina Wieliczko

**Topics:**
- KN From in vitro to in vivo models of biofilm-related bacterial infections
  - AUDE A. FERRAN
- Assessment of amikacin and vancomycin combination efficacy on two *Staphylococcus aureus* strains: a comparison between static and dynamic in vitro methods
  - DIANE C. BROUSSOU, FARID EL GARCH, FREDERIQUE WHOERLE, PIERRE-LOUIS TOUTAIN, ALAIN BOUSQUET-MELOU & AUDE A. FERRAN
- Inhibition of *Salmonella* Typhimurium invasion through downregulation of quorum sensing and virulence genes by methyl gallate
  - BIRUK TESFAYE BIRHANU & SEUNG-CHUN PARK
<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30-10:00</td>
<td>Auditorium</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10:00-11:30</td>
<td>Auditorium</td>
<td>Parallel session 13: ADVANCES IN IMMUNOTHERAPY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Manfred Kietzmann, Wolfgang Bäumer, Krystyna M. Okoniewska</td>
</tr>
<tr>
<td>9:00-10:30</td>
<td>Room B</td>
<td>Parallel session 14: NEW CONCEPTS IN INFECTIOLOGY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Johanna Fink-Gremmels, Marilyn N. Martinez, Luca Guardabassi, Andrzej Górski</td>
</tr>
</tbody>
</table>

**Parallel session 13: ADVANCES IN IMMUNOTHERAPY**

- **O13.1 KN** Canine atopic dermatitis – current treatment and new therapeutic options
  - **Wolfgang Bäumer**

- **O13.2 KN** Experimental models to study immunomodulatory effects
  - **Manfred Kietzmann**

- **O13.3 KN** New tregitopes inducing adaptive regulatory T cells
  - **Krystyna M. Okoniewska, Anna E. Kedzierska, Jakub Okoniewski, Anna Slaweck, Krzysztof Grzymało, Anna Chelmoniska-Soyta, Tomasz Grabowski, Magdalena Ożimek & Piotr Okoniewski**

- **O13.4 KN** Histamine H4 receptor mediates itch through TRPV1 and TRPA1 ion channels
  - **Jenny Wilzopolski, Kristine Roßbach, Santosh K. Mishra, Wolfgang Bäumer & Manfred Kietzmann**

- **O13.5 KN** Neuromedin B: characterization of a novel peripheral pruritogen
  - **Sarah Ehlöing, Mei-Chuan Kuo, Tomoki Fukuyama, Thierry Olivry & Wolfgang Bäumer**

**Parallel session 12: RESIDUES AND CONTAMINANTS**

- **O12.1 KN** Bisphenol S, used as Bisphenol A alternative, accumulates in the fetal compartment throughout gestation
  - **Florence C. Grandin, Marie-Léa Z. Lacroix, Véronique Gatrad, Catherine Viguié, Hanna Mila, Pierre-Louis Toutain & Nicole Picard-Hagen**

- **O12.2 KN** Determination of selected polychlorinated biphenyl residues in bovine fat, organs and beef via gas chromatography-mass spectrometry
  - **Ozgur Kuzukiran, Ayhan Filazi, Sedat Sevin, Begum Yurdakok-Dikmen Yeliz Yikilmaz, Ekrem Erdogan, Filiz Sen, Esra Totan, Cagan Celik & Ozlem Kirmizibayrak**

- **O12.3 KN** Stereochemistry: a tool to modify pharmacokinetics properties of anticoagulant rodenticides without modifying their efficiency
  - **Etienne Benoît, Isabelle Fourel & Virginie Lattard**

- **O12.4 KN** Outbreak of oleander poisoning (*Nerium oleander*) in dairy cattle
  - **Carlo Nebbia, Flavia Girolami, Maria Teresa Capucchio, Elena Biasibetti, Luigi Ceci, Grazia Carelli, Fabrizio Iarussi, Fabio Gosetti & Emilio Marengo**

- **O12.5 KN** The composition of drinking water and feeding systems for oral group medication in 52 Belgian swine herds, in relation to homogeneity, stability and cross-contamination of veterinary medicinal products
  - **Femke Vandael, Jeroen Dewulf, Els Daeseleire, Mia Eeckhout, Patrick De Backer, Mathias Devreeve & Siska Croubels**
<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
</table>
| 10:00-11:30| Room C       | Parallel session 15: MYCOTOXINS  
Chairpersons: Carlo Nebbia, Flavia Girolami, Piotr Jedziniak |
| O15.1     |              | KN Mycotoxins in animal feed – do we really know how to manage this issue? PIOTR JEDZINIAK |
| O15.2     |              | Protection against AFB1 cytotoxicity by natural antioxidants in primary cultures of bovine mammary gland FLAVIA GIROLAMI, SHIVA GHADIRI, EUGENIO MARTIGNANI, VERONICA SPALENZA, PAOLA BADINO & CARLO NEBBIA |
| O15.3     |              | The effect of chlorophyllin on deoxynivalenol absorption in porcine jejenum explants MARTA MENDEL, WOJCIECH KARLIK, MAGDALENA CHLEOPECKA, KATARZYNA JABŁOŃSKA & URSZULA LATEK |
| O15.4     |              | Role of delta-tocotrienol on ochratoxin-A induced nephrotoxicity and oxidative stress in rat SARA DAMIANO, PATRIZIA LOMBARDI, SALVATORE FLORIO & ROBERTO CIARCA |
| O15.5     |              | PKA/CREB and NF-κB pathways regulate AKNA transcription: a novel insight into T-2 toxin-induced inflammation and GH deficiency XU WANG, XIANGLIAN LIU, DEYU HUANG, PU GUO, MENGHONG DAI, HAIHONG HAO, SHUYU XIE & ZONGHUI YUAN |
| 11:30-12:00|              | Coffee break |
| 12:00-13:30| Auditorium   | Parallel session 16: BIOTRANSFORMATION AND DRUG TRANSPORTERS  
Chairpersons: Mauro Dacasto, Johanna Fink-Gremmels, Marta Mendel |
| O16.1     |              | Comparative N-demethylation of malachite green and leucomalachite green in trout and rat liver microsomes CARLO NEBBIA, FLAVIA GIROLAMI, PAOLA BADINO, MONICA CARLETTI & ALESSANDRA GIULIANO ALBO |
| O16.2     |              | Maturation of hepatic cytochrome P450 enzymes in conventional pigs: fact or fiction? JOSKE MILLECAM, LAURA DE CLERCK, ELISABETH GOVAERT, MATTHIAS DEVREESE, ELKE GASTHUYYS, WIM SCHELSTRAETE, DIETER DEFORCE, LIES DE BOCK, JAN VAN BOXLAER, STANISLAS SYS, SISKA CROUBELS |
| O16.3     |              | Cytochrome P450 3As (CYP3As) genotyping in Piedmontese and Limousine cattle breeds MERY GIANTIN, ROBERTA TOLOSI & MAURO DACASTO |
| 12:00-13:30| Room C       | Parallel session 18: ADVANCES IN COMPANION ANIMAL MEDICINE  
Chairpersons: Petra Cagnardi, Aneliya Milanova, Jerzy Jaroszewski |
<p>| O18.1     |              | KN Rational use of antimicrobials for surgical prophylaxis PETRA CAGNARDI |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>Auditorium</td>
<td><strong>Parallel session 19: TRANSLATIONAL MEDICINE &amp; PHARMACOTHERAPY OF MINOR SPECIES</strong>&lt;br&gt;chairpersons: Mario Giorgi, Lloyd Reeves- Johnson, Tomas Maślanka</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O18.2 Development of a nested K-PD model to characterize the effect of oral rivaroxaban on the interlinked time-courses of coagulation variables in dogs</strong>&lt;br&gt;BÉRÉNICE CONVERSY, MARIE-CLAUDE BLAIS, MARILYN DUNN, CAROLYN GARA-BOIVIN &amp; JÉRÔME R. E. DEL CASTILLO</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O18.3 Treatment of ocular disorders in dogs can be influenced by ABC efflux transporters and cyclooxygenase (COX) enzymes</strong>&lt;br&gt;ANELIYA MILANOVA, Svetozar KRUSTEV &amp; JOHANNA FINK-GREMELS</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O18.4 Tolerance and pharmacokinetics of Galliprant&lt;sup&gt;™&lt;/sup&gt; administered orally to Mdr1-deficient collies</strong>&lt;br&gt;MARK C. HEIT, L JAY STALLONS &amp; PATRICK BROSSARD</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O18.5 Chewable, compliance-friendly medicinal formulations</strong>&lt;br&gt;KURT I. DRAGET, SIRE FORS GRØNNO &amp; MARC VAN MARIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O18.6 Development of a nested K-PD model to characterize the effect of oral rivaroxaban on the interlinked time-courses of coagulation variables in dogs</strong>&lt;br&gt;BÉRÉNICE CONVERSY, MARIE-CLAUDE BLAIS, MARILYN DUNN, CAROLYN GARA-BOIVIN &amp; JÉRÔME R. E. DEL CASTILLO</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O18.7 Treatment of ocular disorders in dogs can be influenced by ABC efflux transporters and cyclooxygenase (COX) enzymes</strong>&lt;br&gt;ANELIYA MILANOVA, Svetozar KRUSTEV &amp; JOHANNA FINK-GREMELS</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O18.8 Tolerance and pharmacokinetics of Galliprant&lt;sup&gt;™&lt;/sup&gt; administered orally to Mdr1-deficient collies</strong>&lt;br&gt;MARK C. HEIT, L JAY STALLONS &amp; PATRICK BROSSARD</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O18.9 Chewable, compliance-friendly medicinal formulations</strong>&lt;br&gt;KURT I. DRAGET, SIRE FORS GRØNNO &amp; MARC VAN MARIS</td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>Room B</td>
<td><strong>Parallel session 20: IN VITRO MODELS IN PHARMACOLOGY &amp; TOXICOLOGY</strong>&lt;br&gt;chairpersons: Aletta D. Kraneveld, Maria-Aranzazu Martinez, Wojciech Karlik</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O19.1 Extrapolation of drug-dosing regimens from major to minor production species: an efficacy trial with dietary chlorotetracycline against respiratory pasteurellosis in farmed rabbits</strong>&lt;br&gt;DOAA S. NOUH, MARIE-ODILE BENOIT-BIANCAMANO &amp; JÉRÔME R. E. DEL CASTILLO</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O19.2 Pharmacokinetics of marbofloxacin in freshwater crocodiles (Crocodylus siamensis)</strong>&lt;br&gt;AMNART POAPOLATHEP, SARANYA POAPOLATHEP, NARUMOL KLANGKAEW, SUPANNIKA HANTRAKUL, PIYALUK SINPHITHAKKUL, NAPASORN PAOCHOOSAK &amp; MARIO GIORGI</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O19.3 Comparative pharmacokinetics of oxytetracycline in tilapia (Oreochromis spp.) raised at three different salinities</strong>&lt;br&gt;PRITAM SIDHU, STEPHEN SMITH, CORINNE MAYER, GERALDINE MAGNIN, DAVID KUHN &amp; JOHANN COETZEE</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O19.4 Canine organoids for drug efficacy and safety testing: an innovative preclinical model for drug development</strong>&lt;br&gt;JONATHAN P. MOCHEL, ALBERT E. JERGENS, LAWRENCE CHANDRA, DAWN KINGSBURY, TODD AHERLEY, AGNES MOCHEL, MARTIN E. FERNANDEZ-ZAPICO, KENNETH WANG, HYUN JUNG KIM &amp; KARIN ALLENSPACH</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O19.5 The development of a juvenile porcine augmented renal clearance model for paediatric drug research during sepsis: the effect of different continuously administered LPS doses on the renal function</strong>&lt;br&gt;LAURA DHONDT, SISKA CROUBELS, PIETER DE COCK, PETER DE PAEPE &amp; MATHIAS DEVREESE</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O19.6 Application of inhalation anesthesia for pharmacokinetics studies in mink</strong>&lt;br&gt;AMIR A. RONAGHINIA, NANNET K. NIKOLAISEN, HELLE H. POULSEN, TINA STRUGE, CONNIE F. MATTHEISEN, ANNE SOFIE V. HAMMER, CARSTEN GRØNDAL, STINE G. HANSEN, PIERRE-LOUIS TOUTAIN &amp; PETER DAMBORG</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O19.7 3D printing and the future of development of animal health products</strong>&lt;br&gt;ROMEL VELEV, FILIP TRAJKOVSKI, NATASHA KRLEŠKA-VELEVA, VITOMIR ĆUPIĆ &amp; DEJANA ĆUPIĆ-MILADINOVIĆ</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>O19.8 Preliminary characterisation of a novel cattle foetal hepatocyte-derived cell line (BFH12)</strong>&lt;br&gt;MERY GIANTIN, ROBERTA TOLOSI, AXEL SCHOENIGER, HERBERT FUHRMANN &amp; MAURO DACASTO</td>
</tr>
<tr>
<td>Time</td>
<td>Room / Venue</td>
<td>Details</td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>16:30</td>
<td>VIP Room</td>
<td>JVPT Journal meeting</td>
</tr>
<tr>
<td>17:30</td>
<td>Room C</td>
<td>ECVPT general assembly</td>
</tr>
<tr>
<td>20:00</td>
<td>Topacz Castle</td>
<td>Gala dinner</td>
</tr>
</tbody>
</table>

**Day 4: Wednesday, 27th June**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-9:30</td>
<td>Auditorium</td>
<td>Parallel session 22: ANTIPARASITICS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Carlos E. Lanusse, Richard J. Martin, Piotr Okoniewski</td>
</tr>
<tr>
<td>O22.1 KN Worm War: Developing a better understanding of the pharmacology of anthelmintics</td>
<td>Richard J. Martin</td>
<td></td>
</tr>
<tr>
<td>O22.2 Modulation of metabolic and transport processes: A valuable tool for improving anthelmintic efficacy?</td>
<td>Paula Viviani, Guillermo L. Virkel, Sonia E. Luque, Mercedes Llóberas, Carlos E. Lanusse &amp; Adrián L. Lifschitz</td>
<td></td>
</tr>
<tr>
<td>O22.3 Old drugs for new uses: pharmacokinetic assessment to support oxfendazole repurposing as a flukicidal compound</td>
<td>Laura Ceballos, Candida Canton, Valeria Gayo, Laura Moreno, Paula Domínguez, Carlos Lanusse &amp; Luis Alvarez</td>
<td></td>
</tr>
<tr>
<td>O22.4 Efficacy of pyrantel and fenbendazol against Parascaris univalens infection in foals in Sweden</td>
<td>Eva Tydén, Olivia Rasmussen, Tomas Bergström, Johan Höglund &amp; Frida Martin</td>
<td></td>
</tr>
<tr>
<td>O22.5 Natural bioactive compounds as an alternative to control ectoparasites of veterinary importance</td>
<td>Mohaddeh A. Tabari, Mohammad R. Yousefi, Filippo Maggi &amp; Giovanni Benelli</td>
<td></td>
</tr>
</tbody>
</table>

### EAVPT 2018 Detailed programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-16:00</td>
<td>Room C</td>
<td>Parallel session 21: TEACHING WORKSHOP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Arno H. Werners, Marta Tikhomirov</td>
</tr>
<tr>
<td>O21.1 KN A changing demand on our profession; how to align educational approaches to pharmacology and toxicology with current competency frameworks?</td>
<td>Louska Schipper &amp; Arno H. Werners</td>
<td></td>
</tr>
<tr>
<td>O21.2 Development of a new innovative educational methods in pharmacology and toxicology at the veterinary school of Lyon: application to good practice in antibacterial prescription</td>
<td>Caroline Prouillac, Zorée Djeouadji &amp; Philippe Berny</td>
<td></td>
</tr>
</tbody>
</table>

### Brainstorming Session (Zoetis):

- Validation of Biomarkers and Use in Pivotal Clinical Studies
- Scott Brown & Michael Stegemann

### Coffee Break

- 16:00-16:30

### Poster session 3 (Chairperson: Carlo Nebbia)

- P9 Drug residues
- P10 Antimicrobial susceptibility testing

### Poster session 4 (Chairperson: Mauro Dacasto)

- P11 Pharmacokinetics – general
- P12 Biotransformation & transporters
- P13 Modelling & simulation

### Poster session 5 (Chairperson: Jonathan Elliott)

- P14 Immunopharmacology and biologics
- P15 Pharmacodynamics – general
- P16 Pain and inflammation
- P17 Regulatory affairs
<table>
<thead>
<tr>
<th>Time</th>
<th>Room / Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-9:30</td>
<td>Room C</td>
<td>Parallel session 24: GUT HEALTH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Alejandro L. Soraci, Aletta D. Kraneveld, Błażej Poźniak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O24.1 KN Understanding the impact of gut health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aletta D. Kraneveld</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O24.2 Effect of Cynara scolymus extract on histomorphological parameters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and main species of intestinal bacteria in weaning piglets</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Guadalupe Martínez, Susana N. Diéguez, María B. Fernández Paggi,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Denisa S. Pérez Gaudí, Julieta M. Decundo, Agustina Romanelli, Fabián</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Amanto &amp; Alejandro L. Soraci</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O24.3 The deficiency of Lon protease decreases the susceptibility of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>clinical isolates of <em>Salmonella enterica</em> Serovar Typhimurium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yawei Sun, Lei Yang, Xuefeng Yang, Yanzhao Xu, Bolin Hang, Yonzhu Hu,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gongzheng Hu</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O24.4 Synergistic interaction between methyl gallate and tylosin against</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Salmonella Typhimurium</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abraham F. Mechesso, Park S. Chun</td>
</tr>
<tr>
<td>9:30-10:00</td>
<td>Auditorium</td>
<td>Zoetis Session:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monoclonal Antibody Therapeutics in Veterinary Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michael Stegemann &amp; Scott Brown</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td></td>
<td>Coffee break</td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>Auditorium</td>
<td>Plenary lectures</td>
</tr>
<tr>
<td></td>
<td></td>
<td>chairpersons: Pierre-Louis Toutain, Johanna Fink–Gremmels</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td>PL.5 Anthelmintic resistance – a challenge to the health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and well-being of animals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Norbert Mencke</td>
</tr>
<tr>
<td>11:15</td>
<td></td>
<td>PL.6 Contribution of –<em>omics</em> methodologies to veterinary pharmacology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and toxicology, with special emphasis on drug metabolizing enzymes and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>drug transporters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mauro Dacasto &amp; Mery Giantin</td>
</tr>
<tr>
<td>Time</td>
<td>Room / Venue</td>
<td>Details</td>
</tr>
<tr>
<td>----------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 12:00-13:00 | Auditorium  | **Session of residents:** ADVANCES OF VETERINARY PHARMACOLOGY & TOXICOLOGY  
  chairpersons: Jonathan P. Mochel, Lloyd Reeve-Johnson  
  O25.1 RL The emerging issue of AFB1 in temperate countries: a One-Health perspective  
  FLAVIA GIROLAMI  
  O25.2 RL Chronic infections and *in vitro* optimization of current antibiotics treatments: focus on *Staphylococcus aureus*  
  DIANE C. BROUSSOU  
  O25.3 RL Total Liquid Ventilation: potential applications in veterinary medicine  
  MATTHIAS KOHLHAUER |
| 13:00    | Room A       | Closing ceremony of the 14th EAVPT Congress                             |
| 13:30    |              | Lunch                                                                   |
For more than 80 years, Vetoquinol has been promoting animal protection and well-being. To this end, we develop, manufacture and market veterinary medicines and non-medicinal products with a permanent desire to innovate and be close to our clients.

VETOQUINOL SA
BP 189
70204 LURE CEDEX
FRANCE

frederique.woehrle@vetoquinol.com
www.vetoquinol.com

Ceva Santé Animale is a fast growing, global animal healthcare company, focused on the research, development production and marketing of vaccines and pharmaceutical products for companion animals, livestock, swine and poultry. Driven to innovate and with a proven record of double-digit growth, Ceva is one of the fastest growing top 10 animal healthcare companies. Our vision reaches far beyond animal health and welfare. It’s estimated that a staggering 75% of all emerging human infectious diseases originate from animals and birds. These zoonoses, as they’re known, are what compel us to innovate – to succeed in the fight against the likes of avian flu, brucellosis and Q-fever. They’re one of the driving forces behind our vision: “Together, beyond animal health”.

Ceva Santé Animale
10, avenue de la Ballastière
33500 LIBOURNE
FRANCE

contact@ceva.com
contact@ceva.com

Zoetis is a leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in Animal Health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests and biodevices and supported by a range of services with sales in more than 100 countries. With our singular focus on animal health, we strive to make our products, services, and people the most valued by our veterinarian and livestock producer customers around the world.

Research and Development is at the core of our efforts to provide innovation outcomes that help veterinarians and livestock producers better predict, prevent, detect and treat disease as well as maximize healthy performance and production. The Zoetis R&D organization is comprised of scientific experts who leverage state-of-the-art research facilities, the latest technologies and innovative approaches to deliver integrated health solutions to our customers. To learn how to become a partner with Zoetis, please visit http://www.zoetis.com/innovation/strategic-partnerships/become-a-partner.

Zoetis
10 Sylvan Way
Parsippany, NJ 07054
USA

zoetismedia@zoetis.com
www.zoetis.com

Globally, Bayer is one of the leading life science companies and a driving force in the health and well-being of people and animals. Founded in 1863 by chemist Friedrich Bayer and his brother, Wilhelm, the company has grown into one of the largest pharmaceutical companies and a leading life science company for agriculture and animal health.

Based in Germany and a business unit of Bayer AG, Bayer Animal Health is the #5 animal health company globally with revenues of €1.6 billion in FY2017. It offers a broad range of products, with a particularly strong position in the field of parasiticides for companion animals, and parasiticides and anti-infectives for the treatment of infectious diseases in livestock. Bayer Animal Health sells products in over 120 countries and has over 3,500 employees worldwide.

Bayer Animal Health
Kaiser-Wilhelm-Allee 10
51373 Leverkusen
Germany

info@bayer.com
animalhealth.bayer.com
Elanco Animal Health provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,250 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana, U.S. Visit us at Elanco.com and EnoughMovement.com.

Boehringer Ingelheim Animal Health Business Unit
Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of €3.9 billion and around 10,000 employees worldwide, we are present in more than 150 markets.

Avogadro LS is an international Contract Research Organization with 20 years of experience that offers a broad portfolio of In Life studies for human and veterinary drug development.

Our services encompass: metabolism / pharmacokinetic, safety / efficacy and bioanalysis studies.

Our team is committed to providing accurate scientific solutions of the highest quality, while forming a cohesive relationship with its clients.

With 9 500 m² / 100 000 ft², our European & US facilities are modular & adapted for all preclinical & clinical studies including vaccine challenge studies.

AAAALAC & GLP accreditations / ABSL2 - BSL2 areas.

Avogadro LS
Parc de Génibrat
31470 Fontenilles
France
sales@avogadrols.com
sales@avogadrols.com

KindredBio is a biopharmaceutical animal health company. KindredBio is focused on bringing breakthrough human products and innovative new technologies to veterinary medicine to address unmet clinical needs and provide benefits to animal companions. Our core strategy is to leverage the billions of dollars that have been invested by other companies in human pharmaceuticals by modifying, improving, and repurposing pre-existing drugs and therapeutics that have already proven to be safe and effective in humans. For example, we are developing felinized, caninized and equinized versions of proven human biologics.

Animal companions are an integral part of life and are considered members of the family. We are a pioneer in the animal biotech field, and we are fortunate to have one of the best scientific teams and pipelines in the industry. Our goal is to continue to build on our leadership and leverage opportunities in veterinary medicine to meet unmet needs for our animal companions.

Kindred Biosciences Inc.
1555 Bayshore Hwy; Ste 200
Burlingame, CA 94010
USA
www.kindredbio.com

Avogadro LS
Parc de Génibrat
31470 Fontenilles
France
sales@avogadrols.com
sales@avogadrols.com

Sponsor profile

We support our clients in the development and maintenance of Products for the Animal Health & Nutrition market from the idea to marketing authorization. We establish pre-clinical and clinical development plans based on a profound regulatory and business strategy, placing formulation development with our partners and conducting all needed studies. Our Regulatory Affairs group will lead you through all legislative requirements to get your dossier filed and to meet all standards requested for a fast and efficient way to market. Multinational veterinary clinical studies are one of our core expertise. Our multi-disciplinary team is built on veterinarians working as product developers, regulatory affairs specialists, clinical monitors, quality auditors & data managers.

FATRO - Animal health, your health
Founded in 1947, FATRO is a pharmaceutical company operating exclusively in Veterinary Medicine. The beating heart of its research facilities and its main production plants are situated in Italy: the plant near Bologna produces drugs and vaccines for all animal species, that near Brescia is a specialist hub for the production of poultry vaccines. Currently the Group has over 700 employees throughout the world, of whom a large part are young. FATRO invests continually in Research and Development, marketing high-quality products which are appreciated throughout the world. It exports to over 90 countries and has its own subsidiary companies in Poland, Spain, Greece, the Czech Republic, Argentina, Uruguay and India. The FATRO Group is experiencing continual growth, a demonstration of its dynamism and its vision of the future.

Virbac

Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical laboratory since always dedicated to animal health. Currently ranked 7th worldwide, the company is present in more than 100 countries, offering a comprehensive and practical range of products and services covering the majority of species and pathologies. Virbac innovation, based on both technological advances and listening to the customers, relies on reactive production facilities which meet the highest international quality standards. For nearly fifty years, these specific features have allowed the company to build a personalized relationship with veterinarians and farmers in every country. Through this privileged partnership, in which social, health and environmental issues come together, Virbac contributes, day after day, to shape the future of animal health.

ThothPro

ThothPro is an IT company established in 2014 by industry and academic professionals, with a goal to deliver easy to use yet efficient software solutions for pharmacokinetic calculations and modelling. We incorporate latest research results and we use modern programming tools to create intuitive, compact software which minimizes the time needed to perform analyses by users. Custom solutions are also available.
Exhibitors profile

Biowet Drwalew SA is the joint stock company of long-time history and well-established market position among manufacturers of the wide variety of medicines for animals in Poland. Biowet Drwalew specializes in the production of ointments and calcium preparations occupying the first position in the whole-country ranking. The firm sells its products in Poland through the wide network of authorized veterinary wholesale, establishments covering the whole territory of Poland. The majority of the products are manufactured meeting the community GMP and WHO requirements of superior quality. Since January 2006 Biowet Drwalew has been in the possession of the GMP certificate for powdered products.

Biowet Puławy Ltd. is fully Polish modern veterinary medicine production plant. Our operations protect health of both animals and people. We supply latest generation effective and safe medicine for veterinary services, farming and breeding sectors.

As of present we offer more than 50 preparations, including vaccines, diagnostic preparations, antibiotics, calcium preparations, sulphonamides, antiparasitic preparations, mineral and vitamin supplements and a number of other specialized groups of medicines for multiple species of animals.


Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Biofaktor was established in 2000 and is a pharmaceutical plant, which manufactures antibiotics, sulfonamides, compound feeds, dietary supplements, syrups, ointments and creams, suppositories and vaginal globules. Both plants have integrated quality assurance systems such as: GMP, HACCP, ISO 9001:2008. Plant in Gorzów Wielkopolski has additionally CE certificate for medical devices according to EN ISO 13485:2012 and AC 2012 and Medical Device Directive 93/42/EEC.

Biofaktor has more than 160 products under own brand and over 30 veterinary medicines registered in various countries around the world.

As a contract manufacturer we offer various forms of products under the private labels of our clients.

We constantly look for new partners. Would you like to work with us? Feel free to contact us at any time!

Biowet Puławy Sp. z o.o.
H. Arciucha 2
24-100 Puławy
Poland

sekretariat@biowet.pl
www.biowet.pl

Charles River
251 Ballardvale Street
Wilmington MA 01887
USA

globalevents@crl.com
www.criver.com

Biofaktor sp. z o.o.
Czysta 4
96-100 Skierniewice
Poland

info@biofaktor.pl
www.biofaktor.pl/en/

Biofaktor Sp. z o.o.

Biofaktor was established in 2000 and is a pharmaceutical plant, which manufactures antibiotics, sulfonamides, compound feeds, dietary supplements, syrups, ointments and creams, suppositories and vaginal globules. Both plants have integrated quality assurance systems such as: GMP, HACCP, ISO 9001:2008. Plant in Gorzów Wielkopolski has additionally CE certificate for medical devices according to EN ISO 13485:2012 and AC 2012 and Medical Device Directive 93/42/EEC.

Biofaktor has more than 160 products under own brand and over 30 veterinary medicines registered in various countries around the world.

As a contract manufacturer we offer various forms of products under the private labels of our clients.

We constantly look for new partners. Would you like to work with us? Feel free to contact us at any time!

Biofaktor was established in 2000 and is a pharmaceutical plant, which manufactures antibiotics, sulfonamides, compound feeds, dietary supplements, syrups, ointments and creams, suppositories and vaginal globules. Both plants have integrated quality assurance systems such as: GMP, HACCP, ISO 9001:2008. Plant in Gorzów Wielkopolski has additionally CE certificate for medical devices according to EN ISO 13485:2012 and AC 2012 and Medical Device Directive 93/42/EEC.

Biofaktor has more than 160 products under own brand and over 30 veterinary medicines registered in various countries around the world.

As a contract manufacturer we offer various forms of products under the private labels of our clients.

We constantly look for new partners. Would you like to work with us? Feel free to contact us at any time!

Biofaktor was established in 2000 and is a pharmaceutical plant, which manufactures antibiotics, sulfonamides, compound feeds, dietary supplements, syrups, ointments and creams, suppositories and vaginal globules. Both plants have integrated quality assurance systems such as: GMP, HACCP, ISO 9001:2008. Plant in Gorzów Wielkopolski has additionally CE certificate for medical devices according to EN ISO 13485:2012 and AC 2012 and Medical Device Directive 93/42/EEC.

Biofaktor has more than 160 products under own brand and over 30 veterinary medicines registered in various countries around the world.

As a contract manufacturer we offer various forms of products under the private labels of our clients.

We constantly look for new partners. Would you like to work with us? Feel free to contact us at any time!
Exhibitor profile

MSD Animal Health is a research-driven company that develops, manufactures and markets a broad range of veterinary medicines and services. We offer one of the industry's most innovative portfolios, spanning products for the prevention, treatment and control of disease in all major farm and companion animal species. We successfully market our products in more than 140 countries and operate a network of manufacturing sites and research and development (R&D) facilities around the world.

Ouraim is to create value and contribute to the ongoing success of our customers and earn their trust every day. By listening carefully to all our stakeholders and putting customer satisfaction at the core of our business, we provide innovative, high-quality and, above all, solutions-driven products and services for farm and companion animal species.

By consistently delivering the highest standards of quality, professionalism and integrity, our goal is to become the partner of choice for veterinarians, producers and animal owners.

Our products and services enable pets and people to enjoy their time together and will help keep livestock healthy to ensure a safe, wholesome and affordable food supply.

Middle East For Vaccines (ME VAC) is the First private Facility for Veterinary Vaccines with Egyptian International partnership, ME VAC is GMP, ISO 9001, ISO 14001, ISO 18001 Accredited, ME VAC Produce Poultry Vaccines, Ruminants Vaccines, Equine Vaccines, Aqua Vaccines

Middle East For Vaccines (ME VAC)
20 Joseph Teto, El Nozha El gdeda
Cairo
Egypt
marketing@me-vac.com
www.me-vac.org

Pharmaceutical Company Okoniewscy Ltd. is based in Bielawa in Lower Silesia.

It was established in 1990, currently specializes in four segments: veterinary medicine, dentistry and pharmacy and laboratory.

To meet market needs, developing a line of skin care products and vitamin supplements for companion animals.

The company has 26 stores and patent claims.

Quality policy we accept as superior to our business. To achieve this systematically introduce principles of Good Manufacturing Practice GMP (Good Manufacturing Practice) is necessary to ensure the quality of our drugs and formulations.

We make every effort to ensure that our products are of the highest quality. We declare full responsibility for manufactured by our company products, with all the consequences of this commitment.

Taken priority in our business is to strive for complete satisfaction of our customers.

Middle East For Vaccines (ME VAC)
20 Joseph Teto, El Nozha El gdeda
Cairo
Egypt
marketing@me-vac.com
www.me-vac.org

PFO Vetos-Farma Sp. z o.o.
Dzierżoniowska 21
58-260 Bielawa
Poland
biuro@vetos-farma.com.pl
vetos-farma.com.pl

Primacyt Cell Culture Technology GmbH
Hagenower Str. 73
19061 Schwerin
Federal Republic of Germany
info@primacyt.de
www.primacyt.com
www.primacyt.services

Primacyt Cell Culture Technology
GmbH
Hagenower Str. 73
19061 Schwerin
Federal Republic of Germany
info@primacyt.de
www.primacyt.com
www.primacyt.services

Primacyt is a German biotechnology company and contract researcher. We offer biological matrices, skin explants, in vitro technologies and assay systems for applications in human and animal health, and environmental toxicology. Liver cells, microsomes, and S9 fractions are provided from human, monkey, dog, minipig, rat, mouse, domestic farm animals (horse, cattle, sheep, goat), birds (duck, chicken, turkey), and fish (salmon and trout).

We are GLP certified and provide contract research for pharmaceutical, biotech, chemical, and cosmetics industries. We have established a technology platform to assay uptake and efflux transporter activities in stable transfected HEK293-cell lines and primary hepatocytes. We are an EU reference lab for the Validation of Alternatives to Animal Experiments.

Primacyt is a German biotechnology company and contract researcher. We offer biological matrices, skin explants, in vitro technologies and assay systems for applications in human and animal health, and environmental toxicology. Liver cells, microsomes, and S9 fractions are provided from human, monkey, dog, minipig, rat, mouse, domestic farm animals (horse, cattle, sheep, goat), birds (duck, chicken, turkey), and fish (salmon and trout).

We are GLP certified and provide contract research for pharmaceutical, biotech, chemical, and cosmetics industries. We have established a technology platform to assay uptake and efflux transporter activities in stable transfected HEK293-cell lines and primary hepatocytes. We are an EU reference lab for the Validation of Alternatives to Animal Experiments.
Exhibitors profile

Randox Food Diagnostics continue to transform the landscape of conventional screening and wine analysis by developing revolutionary, high quality products. Randox Food is dedicated to improving the global food safety chain. Our versatile range of kits includes an extensive list of drug residue ELISAs and biochip arrays, as well as our dedicated enzymatic kits for the wine and honey industries.

Vet-Agro Sp. z o.o. is a Polish manufacturer of veterinary drugs, biocidal preparations and other products for animals.

Randox Food Diagnostics
55 Diamond Road
Crumlin
United Kingdom
info@randoxfood.com
randoxfood.com

Vet-Agro Sp. z o.o.
Melgiewska 18
20-234 Lublin
Poland
vet-agro@vet-agro.pl
www.vet-agro.pl

Vet-Agro Sp. z o.o.
Melgiewska 18
20-234 Lublin
Poland
vet-agro@vet-agro.pl
www.vet-agro.pl

VRM is a specialist veterinary research management company providing proven, veterinary specific, project management expertise to Animal Health companies worldwide.

We work with clients to optimise their pharmaceutical, biological, biotechnological, medicated feed and diagnostic product development programmes with the objective of accelerating timelines to successful product registration in major markets.

We have experience in the development and registration of novel products and generics for livestock and companion animals in Europe, N. America, Australia, New Zealand and Japan.

VRM has direct access to top class northern and southern hemisphere contract research organisations (allowing year round conduct of otherwise seasonal animal studies) and highly experienced scientific writers.

Veterinary Research Management (VRM) Ltd
The Mews Studio, Portland Road
Malvern WR14 2TA
UK
info@vrm.uk.com
www.vrm.uk.com

Veterinary Research Management (VRM) Ltd
The Mews Studio, Portland Road
Malvern WR14 2TA
UK
info@vrm.uk.com
www.vrm.uk.com

Vetspin S.r.l.
Via Toscanini, 9
40055 Castenaso
Italy
infoservice@vetspin.com
www.vetspin.com

Vetspin is a veterinary CRO that performs GLP safety and GCP efficacy studies on farm animals, including cattle, pigs, sheep, poultry and rabbits: studies on target animal safety, pharmacokinetics, bioequivalence, and residue depletion; studies on dose determination/confirmation in infected animals; studies on efficacy of drugs in field; studies on safety and efficacy of poultry vaccines.

The Animal Care Unit is regularly inspected by Italian authorities and is subjected to a rigorous auditing schedule to ensure continuous conformity with the quality system.

The Diagnostic Laboratory holds high and qualified skills in clinical tests.

The Bioanalytical Laboratory of Vetspin is specialized in development and validation of methods for the analysis of veterinary drugs in various biological matrices (plasma, muscle, liver, kidney, fat, fat + skin, milk, eggs, manure).
Up to 9 posters from the Sections P1-P3 will be orally presented during the session 1 (Monday, Room B, 4 pm – 5 pm)

Evaluation Committee 1
Jérôme R. E. Del Castillo (Chairperson), Frédérique Woehrlé, Carlos Lanusse, Gong-Zheng Hu, Tomasz Grabowski

Section P1 : ANTIBIOTICS

P1.1 Synergistic effects of antibacterials and histamine H1 ligands on *Escherichia coli*
GUSTAV G. BRUER, JESSICA MEIßNER, PAULA HAGEDORN, EILEEN SCHULTZ, VIVIANE FILOR, STEFANIE MIELKE-KUSCHOW & MANFRED KIETZMANN

P1.2 Influence of amoxicillin's metabolites on amoxicillin antimicrobial activity in vitro
MAGDALENA OZIMEK, JAKUB OKONIEWSKI, JOANNA KRASIŃSKA, ADAM JUNKA, MARZENNA BARTOSZEWICZ & KRYSZTYNA OKONIEWSKA

P1.3 Marbofloxacin activity against *Escherichia coli* isolated from bovine mastitis: In vitro pharmacokinetic/pharmacodynamic testing, using a hollow fiber system, of a single intramuscular administration of marbofloxacin at 2 different doses, 2 mg/kg and 10 mg/kg
FARID EL GARCH, DIANE BROUSSOU, MARC SCHNEIDER & FREDERIQUE WOEHRLÉ

P1.4 Implications for dosing regimen of enrofloxacin administered concurrently with dexamethasone to febrile cattle calves
PRITAM K. SIDHU, BALAJE RAMALINGAM, GURPREET KAUR, SATYAYAN RAMPAL & JOHANN F. COETZÉE

P1.5 Flaxseed-enriched diets reduce levels of the antimicrobial danofloxacin in ovine milk
ANA I. ÁLVAREZ, DAFNE GARCÍA-MATEOS, JON A. OTERO, ALBA M. GARCÍA-LINO, INDIRA ÁLVAREZ-FERNÁNDEZ & GRACIA MERINO

P1.6 Disodium fosfomycin concentrations in swine plasma and biophases – an integrated view
DENISA S. PÉREZ GAUDIO, GUADALUPE MARTÍNEZ, MARIÁ B. FERNÁNDEZ PAGGI, JULIETA M. DECUNDO, AGUSTINA ROMANELLI, SUSANA DÍEGUEZ & ALEJANDRO L. SORACI

Poster session 1
Day 2: Monday, 25th June

Up to 9 posters from the Sections P1-P3 will be orally presented during the session 1 (Monday, Room B, 4 pm – 5 pm)

P1.8 Oxytetracycline interaction with water hardness: impact on bioavailability in fed and fasted piglets
JULIETA M. DECUNDO, SUSANA N. DÍEGUEZ, GUADALUPE MARTÍNEZ, AGUSTINA ROMANELLI, MARIÁ B. FERNÁNDEZ PAGGI, DENISA S. PÉREZ GAUDIO, FABIÁN A. AMANTO & ALEJANDRO L. SORACI

P1.9 Efficiency of oral doxycycline medication in weaner pig holdings with recurring respiratory disease outbreaks
JESSICA MEISSNER, PETRA MUELLER, JASMIN BRAUNS, FRANZISKA SCHAEREL, LISA NIEMANN, ROLF NATHAUS, MICHAEL WENDT, KARL-HEINZ WALDMANN

P1.10 Oxytetracycline excretion in sows’ colostrum and milk
MARIÁ B. FERNÁNDEZ PAGGI, SUSANA DÍEGUEZ, JULIETA M. DECUNDO, GUADALUPE MARTÍNEZ, DENISA S. PÉREZ GAUDIO, AGUSTINA ROMANELLI, FABIÁN AMANTO & ALEJANDRO SORACI

P1.11 Treatment of pigs with enrofloxacin via different oral dosage forms – environmental contamination and development of resistance of *Escherichia coli*
PAULA HAGEDORN, JESSICA MEISSNER, GESINE SCHERZ & MANFRED KIETZMANN

P1.12 Impact of a single intramuscular administration of gentamicin at a dose of 3 mg/kg on faecal *Enterobacteriaceae* flora of healthy pigs
FARID EL GARCH, DELPHINE GALLAND & FREDERIQUE WOEHRLÉ

P1.13 Comparison of the effectiveness of various methods of blood sampling and analysis for pharmacokinetics studies of veterinary medicinal products
IHOR KOTS’UMBAS, ZVENISLAVA ZASADNA, SVITLANA MELIKYAN, MARIANA RYDCHUK, YURI KOSENKO & DMYTRO YANOYVYCH

P1.14 Contribution to the characterization of antimicrobial therapy in urinary tract infection in cats: a retrospective study in animals with and without subcutaneous urethral bypass
SOFIA LOURO, SOFIA ZAMITH, TELMO NUNES & BERTA SÃO BRAZ

P1.15 Retrospective study on the use of antibiotics in cats in a French veterinary hospital in 2014 and 2015
HERVÉ POULIQUEN & NADIA CHATEL

P1.16 Retrospective study on the use of antibiotics in dogs in a French veterinary hospital in 2014 and 2015
HERVÉ POULIQUEN & ALEXIA AUBRIL

P1.17 Ecology from farm to fork of microbial drug resistance and transmission. Interventions to reduce antibiotic use in poultry farms
PASCAL SANDERS, CLAIRE CHAUVIN, JULIE DAVID, MAARTEEN DE GUSSEM, NIKOLAI ONGENA, MICHEIL VAN LEUVEN & HILDE VAN MEIRHAEGHE

P1.18 A comparison of Schirmer strips and ophthalmic sponges for quantifying doxycycline in tear fluid of dogs and cats following oral drug administration
LIONEL SEBBAG, LUCAS SHOWMAN, EMILY M MCDOWELL, ANN PERERA & JONATHAN P MOCHEL
Section P2: ANTIPARASITICS

P2.1 A quick and simple method for pyrantel determination in dog plasma by LC-MS/MS
LAURA RICCI BITTI, EVA MORBIDELLI, JULIE RAMBALDI, ANNA ZAGHINI & ANDREA BARBAROSSA

P2.2 An LC-MS/MS method for the determination of ivermectin in dog plasma
LAURA RICCI BITTI, EVA MORBIDELLI, JULIE RAMBALDI, ANNA ZAGHINI & ANDREA BARBAROSSA

P2.3 Exposure evaluation of Fipronil: from pets to fleas
MARLENE Z. LACROIX, EMILIE BOHSIRA, EMMANUEL LIÉNARD, CATHERINE VIGUIE, MICHEL FRANÇ, PIERRE-LOUIS TOUTAIN, ALAIN BOUSQUET-MÉLOU & BÉATRICE B. ROQUES

P2.4 Acaricidal effects of rosemary (*Rosmarinus officinalis*) oil on the hard tick *Haemaphysalis parva* (Acari: Ixodidae)
ANIL YILMAZ, BEGÜM YURDAKÖK-DIKMEN, NURDAN OZER, OLCAY HEKIMOĞLU, OZGUR KUZUKIRAN & AYHAN FILAZI

P2.5 Increased prevalence of *Strongylus vulgaris* after 10 years of target selective treatment in Sweden
EVA TYDÉN, ELIN WERELL, MOA SKARIN, HEIDI ENEMARK, JOHAN HÖGLUND & EVA OSTERMAN LIND

Section P3: PROBIOTICS

P3.1. Probiotic properties of *Lactobacillus plantarum* PSCPL13 from the eel for cultured fish
JIN-YOON KIM & SEUNG-CHUN PARK

P3.2 Effect of oral administration of *Lactobacillus fermentum* culture and magnesium oxide boluses on the dairy cows health parameters and productivity
LAIMA LIEPA & MĀRA VIDUŽA

Poster session 2
Day 2: Monday, 25th June

Up to 9 posters from the Sections P4-P8 will be orally presented during the session 2
(Monday, Room C, 4 pm – 5 pm)

Evaluation Committee 2
Johanna Fink-Gremmels (Chairperson), Juliette Legler, Wolfgang Bäumer, Eran Lavy, Piotr Okoniewski

Section P4: TOXICOLOGY

P4.1 Humboldt penguin’s feathers as bioindicators of metal body burden: a case study
STEFANIA SQUADRONE, PAOLA BRIZIO, LIVIO FAVARO, DANIELA FLORIO, CRISTIANO, DA RUGNA & MARIA C. ABETE

P4.2 Simultaneous determination of creatinine, iohexol and p-aminohippuric acid in animal plasma by ultra-high-performance liquid chromatography–tandem mass spectrometry
LAURA DHONDT, SISKA CROUBELS, PIETER DE COCK, PETER DE PAAPE & MATHIAS DEVREÈSE

P4.3 Illite green clay protects against cytotoxicity in SH-SY5Y cells
BERNARDO LOPEZ-TORRES, IRMA ARES, JOSE-LUIS RODRÍGUEZ, MARTA MARTÍNEZ, DAVID ROURA-MARTÍNEZ, MARÍA-ROSA MARTÍNEZ-LARRANAGA, ARTURO ANADÓN & MARÍA-ARÁNZAZU MARTÍNEZ

P4.4 Counteraction of AFB1 cytotoxicity by natural antioxidants in a mouse liver cell line (AML12)
FLAVIA GIROLAMI, SHIVA GHADIRI, PAOLA BADINO & CARLO NEBBIA

P4.5 *In vitro* toxicity of gentamicin, tobramycin, amikacin and spectinomycin on bovine kidney derived MDBK cell line
ADRIENN M. VERES, ZOLTAN SOMOGYI & AKOS JERZSELE

P4.6 *In vitro* effects of two environmental toxicants, beauvericin and glyphosate in Roundup, on cell proliferation and steroidogenesis using a novel bovine whole ovarian cell culture system
FRANCESCA CALONI, MARIA CHIARA PEREGO, CRISTINA CORTINOVIS, ALESSIA BERTERO & LEON J. SPICER

P4.7 Pesticide poisoning in Portugal: analytical results since 2014 to 2017
ANDREIA M. VERES, ZOLTAN SOMOGYI & AKOS JERZSELE

P4.8 Changes in haematological profile of common carp after three month atrazine exposure
JANA BLAHOVA, VLADIMIRA ENEVOVA, HELENA MODRA & ZDENKA SVOBODOVA

P4.9 Effects of orally administered xylitol in cats
AKOS JERZSELE & ZITA KARANCSE

Section P5: CONTAMINANS

P5.1 Determination of fenobucarb residues in animal and aquatic food products using liquid chromatography-tandem mass spectrometry coupled with a QuECHERS extraction method
JEONG-MIN CHOI, WEJJIA JUNG, SEONG-KWAN KIM, KYUNG-HEE YOO, DA-HEE PARK & HO-CHUL SHIN

P5.2 Determination of polar herbicides in honey by HPLC-QTOF
ALEXANDER SOROKIN, IRINA NESTERENKO, RENAT SELIMOV & ALEXANDER ROMAROV
P5.3 The effects of aflatoxin residues on nutritional contents in ground red chili peppers (*Capsicum annuum*)
AYHAN FILAZI, OZGUR KUZUKIRAN, BEGUM YURDAKOK-DIKMEN, GORKEM OZANSOY-CENGIZ, I. SAFA GURCAN, ERCAN KARABULUT & U. TANSEL SIRELI

P5.4 Effects of phthalates on dog testicular primary cells *in vitro*
BESTE CIL, PINAR ARSLAN, BEGUM YURDAKOK-DIKMEN, KORAY TEKIN, ERGUN AKCAY & AYHAN FILAZI

Section P6: ANTICANCER DRUGS

P6.1 Anticancer activity of novel platinum complex with tris(2-carboxyethyl)phosphine (Pt-TCEP) and its combination with firocoxib or nimesulide
MARTA HENKLEWSKA, ALEKSANDRA PAWLAK, HANNA PRUCHNIK & BOZENA OMBINSKA-MRUKOWICZ

P6.2 Pharmacokinetics of low-dose methotrexate in healthy beagle dogs
ANTOINE ROSTANG, MARION MOSCA, MORGAN JEANNIN, PHILIPPE BERNY, DIDIER PIN & CAROLINE PROUILLAC

P6.3 Early detection of nephrotoxicity after doxorubicin administration in cats
BÁRBARA ABRANTES, GONÇALO VICENTE, TELMO NUNES & BERTA SÃO BRAZ

Section P7: ONE HEALTH & TRANSLATIONAL MEDICINE

P7.1 Development of an atopic march model in Balb/c mice
ANGELIKA SYSAK, FRANÇOIS DAUBEUF, CINDY BARNIG, CHRISTINE LEHALLE & NELLY FROSSARD

P7.2 In vitro biocompatibility of magnetic nanoparticles used as potential drug carriers for implant-directed magnetic drug targeting
DAVID DAHLHAUS, JESSICA MEISSNER, STEFANIE MIELEKUSCHOW, DAWID PETER WARWAS, PETER BEHRENS, JANIN REIFENRATH, NINA ANGRISANI, HILKE CATHERINA JANSEN & MANFRED KIEZTMANN

P7.3 One Health: From Chinese traditional medicine to immunomodulation using astragalus polysaccharides in a model of infectious bursal disease virus in chickens
HONGQUAN LI, JUN-DONG WANG & LLOYD REEVE-JOHNSON

P7.4 A One Health approach to the fracture healing using orthopaedic scaffolds
LOYD REEVE-JOHNSON, MICHAEL SCHUETZ & DIETMAR HUTTMACHER

P7.5 The effect of bee products on Drosophila melanogaster lifespan and mortality
BOŽO RADIĆ, SAŠA RADIĆ, JELENA ŠURAN & FRANE BOŽIĆ

Section P8: ADVANCES IN VETERINARY DRUG FORMULATION

P8.1 Efficacy prediction of four pharmaceutical formulations for intramammary administration containing Aloe vera combined with ceftiofur or cloxacillin in lactating cows
NATALIA FORNO, OSCAR CHACÓN, MARCO MUÑOZ, PAULINA PACHA, DANIELA IRAGÜEN, RUBEÑ MUÑOZ & BETTY SAN MARTÍN

P8.2 The taste preferences of certain synthetic amino acids and meat aromas in cats – a rapid 3-portal acceptance test for testing palatability of flavors in cats
SAILA SAVOLAINEN, JAANA HAUTALA, SARI AIRAKSINEN, ANNE JUPPO, MARJA RAKEKALLIO & OUTI VAINIO

P8.3 Compliance-friendly, voluntarily consumed delivery form
MARCS VAN MARIS, RONALD JAN CORBEE, KAY MØLLER, KURT I. DRAGET & SIRE FORS GRØNMO

P8.4 Effect of submicron trimethoprim particles on the oral bioavailability in pigs
PAULA HAGEDORN, FREDERIK FLACH, JESSICA MEISSNER, JAN HENRIK FINKE, DAVID PILGRAM, ARNO KWADE & MANFRED KIEZTMANN

P8.5 Microparticle entrapped with inclusion complexes suspension for doxycycline hydrochloride and florfenicol sustained release
SHUYU XIE, XIANQIANG LI, DONGMEI CHEN, YULIAN WANG & ZONGHUI YUAN

P8.6 Bioequivalence study between an oral suspension and a tablet formulation of metronidazole following a single oral administration in dogs
TERENCE PELLET, CLAIRE TOUTIN, SANDRINE FOURNEL & PHILIPPE GRUET

Poster session 3
Day 3: Tuesday, 26th June

Up to 9 posters from the Sections P9-P10 will be orally presented during the session 3 (Tuesday, Room A, 4:30 pm – 5:30 pm)

Evaluation Committee 3
Carlo Nebbia (Chairperson), Luca Guardabassi, Murat Cengiz, Jin-Yoon Kim, Błażej Poźniak

Section P9: DRUG RESIDUES

P9.1 Development of a direct competitive ELISA for the detection of lincomycin in milk and milk products
IRINA S. NESTERENKO, KSENIA M. FILIPPOVA, VALENTINA A. SAFRONOVA, YULIYA V. DOBRYAKOVA & ALEXANDER A. KOMAROV

P9.2 Development and validation of an analytical method for the determination of 17β-estradiol residues in tambaqui (*Colossoma macropomum* Cuvier, 1818) by LC-MS/MS and characterization of risk due to consumption of tambaqui treated with this hormone for fish sexual reversion purpose
CELIA A. HOGA, KARINE V. G. RECHE, FERNANDA L. ALMEIDA, VANESSA R. REIS-RAFAELLE, P. CORDEIRO & FELIX G. R. REYES
P9.3 Establishment of a screening method for veterinary anti-microbial agents in animal derived food using liquid chromatography coupled with tandem mass spectrometry

DONGMEI CHEN, SHUYU XIE, JIE YU, YUANHU PAN, LINGLI HUANG & ZONGHUI YUAN

P9.4 Up-regulation of progesterone receptor in formalin fixed sex accessory glands: towards the validation of a screening method for illicit growth promoters abuse inveal calves

ALESSANDRO BENEDETTO, MARZIA PEZZOLATO, SIMONE PELETTO, CHIARA BELTRAMO & ELENA BOZZETTA

P9.5 Illicit treatment in beef cattle. Can a stress oxidative marker give a perspective?

MARZIA PEZZOLATO, RAFFAELLA BARBERO, STEFANIA BERGAGNA, SILVIA Gennero, DANIELA DEZZUTTO, KATIA VARELLO & ELENA BOZZETTA

P9.6 Development and validation of an analytical technique to quantify amitraz in a PVC strip formulation used in Varroa mite control in honey bees

DANIEL REINAUD, VANINA PEREZ, PATRICIO VIDONDO, MARCELO DEL HOYO, CARLOS LANSUSS, LUIS ALVAREZ & LAURA MORENO

P9.7 Determination of exposure to topical drug residues upon petting following repeated topical application of a mirtazapine transdermal ointment in cats

OLIVIER SZKUTA, MELINDA POOLE O’BANION, MIREILLE VILA & MICHELA CANTI souvenir

P9.8 Development, validation and application to real samples of a liquid chromatography – tandem mass spectrometry method for determination of tetracyclines in beeswax

ANNA GAJDA, MAJA ANTCZAK, KAMILA MITROWSKA & ANDRZEJ POSYNIAK

P9.9 Thyrostatic residues determination in thyroid, muscle and urine by LC-MS/MS

ENRICO MIGARONE, GIAN LUCA FERRO, ENRICO PENNAZIO, FEDERICA OLTORO, MARTA LEPORATI, MARZIA PEZZOLATO, DANIELA MARCHIS & MARILENA GILI

P9.10 UniSpray – evaluation of a novel ion source for ionization in veterinary drug analysis

HUBERT ZIÓŁKOWSKI, JAN BOHUSLAVEK, PAVEL SISTI, BARTOSZ RASINSKI & JERZY JAROSZEWSKI

P9.11 Residue analysis of bithionol in animal-derived food products by an effective and rugged extraction method coupled with LC/MS/MS spectrometry

JERZY JAROSZEWSKI, JAN BOHUSLAVEK, PAVEL SISTI, BARTOSZ RASINSKI & NORA MESTORINO

Section P10: ANTIMICROBIAL SUSCEPTIBILITY TESTING

P10.1 Regulation action of cpxR on the susceptibility of Salmonella enterica serovar Typhimurium to colistin

YA-JUN ZHAI, HUI HUANG, JIANH-UA LIU, HUA-RUN SUN, DAN-DAN HE, YU-SHAN PAN & GONG-ZHENG HU

P10.2 Minimum inhibitory concentrations of penicillin and dihydrostreptomycin alone or combined against sow urinary infections isolates

GÉRARD B. B. DE CUYPER, GUILLAUME LEQUEUX, JEAN-CLAUDE PÉGNÉ & MARLÈNE LACREUSETTI

P10.3 Escherichia coli O157:H7 isolated from feedlot-ground beef: bactericidal activity of AP-CECT7121 and synergistic effect with colistin

GASTON DELPECH, MÓNICA CECI, LEONARDO GARCÍA ALLENDE & MÓNICA SPARO

P10.4 Antimicrobial susceptibility of Haemophilus parasuis isolates from pigs in China

ANDREA BUCHAMER, LAURA MARCHETTI, FLORENCIA ALVAREZ, JOSÉ H. VALLIM, MÁRCIA R. ASSALIN, SONIA C. N. QUEIROZ, LOURIVAL C. PARAÍBA, CLAUDIO M. JONSSON & FELIX G. R. REYES

P10.5 Original use of a hollow-fiber infection model to investigate a 5-days antibiotic combination against Staphylococcus aureus biofilm

DIANE C BROUSSOU, MARLÈNE Z LACROIX, PIERRE-LOUIS TOUTAIN, FRÉDÉRIQUE WOEHRLLE, PARID EL GARCH, ALAIN BOUSQUÉT-MELOU & AUDE A FERRAN

P10.6 Novel synergistic antibiotic combinations against multidrug resistant (MDR) Escherichia coli

MURAT CENGIZ, PINAR SAHINTURK, GULCE HEPBOSTANI, SONGUL SONAL & HALIS AKALIN

P10.7 Antimicrobial resistance in Escherichia coli from pet and stray dogs of La Plata, Argentina

ANDREA BUCHAMER, CESAR BORJA, LIHUEL GORTARI, BELÉN ROBERTO, DANIEL BULDAIN, MANUEL CHIRINO TREJO, LAURA MARCHETTI & NORA MESTORINO

P10.8 Combination of cloxacillin and essential oil of Melaleuca armillaris against cloxacillin susceptible Staphylococcus aureus and MRSA

DANIEL BULDAIN, ANDREA BUCHAMER, LAURA MARCHETTI, FLORENCIA ALVAREZ, ARNALDO BANDONI & NORA MESTORINO

P10.9 Metronidazole susceptibility of anaerobic bacteria originating from dogs with periodontal or gastrointestinal diseases

MYRIAM YOUGALA, JAN BOHUSLAVEK, PAVEL SISTI, BARTOSZ RASIŃSKI & NORA MESTORINO
P10.10 Colistin pharmacodynamics in vitro against avian pathogenic Escherichia coli
NA-HYE PARK & SEUNG-CHUN PARK

P10.11 Pharmacodynamic effects of the essential oil of Melaleuca armillaris combined with rifaximin or erythromycin against Staphylococcus aureus
DANIEL BULDAIN, ANDREA BUCHAMER, LAURA MARCHETTI, FLORENCIA ALIVERTI, ARNALDO BANDONI & NORA MESTORINO

P10.12 Melaleuca armillaris Sm. essential oil as adjuvant for erythromycin in acid environment against Staphylococcus aureus
DANIEL BULDAIN, ANDREA BUCHAMER, LAURA MARCHETTI, FLORENCIA ALIVERTI & NORA MESTORINO

P10.13 Lack of experimental evidence to support mcr-1-positive Escherichia coli strain selection during oral administration of colistin by gavage in weaned piglets
ALEXIS VIEL, JÉRÔME HENRI, AGNÈS PERRIN-GUYOMARD, JULIAN LAROCHE, WILLIAM COUET, NICOLAS GRÉGOIRE & MICHEL LAURENTIE

P11.4 Influence of β-cyclodextrins on oral bioavailability of tigecycline in broiler chickens – preliminary study
HUBERT ZIÓŁKOWSKI, HANNA MADEJ-ŚMIECHOWSKA & JERZY JAROSZEWSKI

P11.5 Comparative pharmacokinetics of oral doxycycline in hens of three different productive type breeds
IVELINA PAVLOVA, LUBOMIR LASHEV, RUMYANA MOUTAFCHIEVA, HRISTO LUKANOV & ANELIYA MILANOVA

P11.14 Influence of β-cyclodextrins on oral bioavailability of tigecycline in broiler chickens – preliminary study
HUBERT ZIÓŁKOWSKI, HANNA MADEJ-ŚMIECHOWSKA & JERZY JAROSZEWSKI

P11.15 Comparative pharmacokinetics of oral doxycycline in hens of three different productive type breeds
IVELINA PAVLOVA, LUBOMIR LASHEV, RUMYANA MOUTAFCHIEVA, HRISTO LUKANOV & ANELIYA MILANOVA

P11.16 Synovial and plasma concentrations of benzylpenicillin after intravenous administration of sodium benzylpenicillin in horses
LENA OLSÉN, ANNA OLSÉN & CARINA INGVAST-LARSSON

P11.17 The fate of the metamizole active metabolites in goats and its residues in milk
ANDRES SITOVS, TAE WON KIM, BEATA ŁEBKOWSKA-WIERUSZEWSKA, AMNART POAPOLATHEP, HELEN OWEN, ANDREW LISOWSKI, Z. ABILOVA & MARIO GIORGI

P11.18 Comparative pharmacokinetic study of the metamizole (dipyrone) metabolites in companion animals
TAE WON KIM, BEATA ŁEBKOWSKA-WIERUSZEWSKA, HELEN OWEN, AMNART POAPOLATHEP, MOHADDESEH ABOUHOSSEINI TABARI, BUNNA CHEA, VIRGINIA DE VITO & MARIO GIORGI

P11.19 Comparative pharmacokinetic profiles of cimicoxib in dogs and cats
MARC SCHNEIDER & FREDERIQUE WOEHLRE

P11.20 Pharmacokinetics of dexametomidine combined with ketamine following intramuscular administration in tigers (Panthera tigris)
FEDERICA DI CESARE, PETRA CAGNARDI, LORENA LUCATELLO, ROBERTO VILLA, MICHELE CAPASSO, WILLIAM MAGNONE & GIULIANO RAVASIO

P11.21 Pharmacokinetics of ceftiraxone in the green sea turtle (Chelonia mydas): preliminary study
SARANYA POAPOLATHEP, ROIPIM MAPONGPENG, WEERAPONG LAOVECHPRAKIT, PIYALUK SINPHITHAKKUL, USUMA JERMNAK, CHAINARONG SAKULTHAEW, MARIO GIORGI & AMNART POAPOLATHEP

P11.22 Pharmacokinetics, pharmacodynamics and pharmacokinetic-pharmacodynamic integration of marbofloxacin and methyl gallate
BIRUK TESFAYE BIRHANU & SEUNG-CHUN PARK

P11.23 Pharmacokinetics of florfenicol in turkeys
MARTA TIKHOMIROV, BŁAŻEJ POŹNIAK, ANDRZEJ SMUTKIEWICZ & MARCIN ŚWIATAŁA

P11.24 Pharmacokinetics of meloxicam in lactating goats (Capra hircus) after a single intravenous and intramuscular injection and its quantification in milk
MARIO GIORGI, BEATA ŁEBKOWSKA-WIERUSZEWSKA, ERAN LAVY, ANDRZEJ LISOWSKI, HELEN OWEN & VIRGINIA DE VITO

P11.25 Pharmacokinetics of doxycycline in hens of three different productive type breeds
IVELINA PAVLOVA, LUBOMIR LASHEV, RUMYANA MOUTAFCHIEVA, HRISTO LUKANOV & ANELIYA MILANOVA

P11.26 Pharmacokinetics, pharmacodynamics and pharmacokinetic-pharmacodynamic integration of marbofloxacin and methyl gallate
BIRUK TESFAYE BIRHANU & SEUNG-CHUN PARK

P11.27 Oral absorption profiles of sulfonamides in Shiba goats
KAZUAKI SASAKI, MOHAMED ELBADAWY, YUSUKE ISHIHARA, MOHAMED ABOUBAKR & MINORU SHIMODA

P11.28 Bioavailability of oxytetracycline incorporated to water or feed in weaning piglets
JULIETA M. DECUNDO, SUSANA N. DIÉGUEZ, GUADALUPE MARTÍNEZ, AGUSTINA ROMANELLI, MARÍA E. FERNÁNDEZ PAGGI, DENISA S. PÉREZ GAUDIO, FABIÁN A. AMANTO & ALEJANDRO L. SORACI

P11.29 Pharmacokinetic and pharmacodynamic evaluation of the efficacy of enrofloxacin in treating Salmonella enteritidis infections in broiler chicken
HAE-CHUL PARK, JEONGWOO KANG, KYUNG-HUN JEONG & KWANG-JICK LEE
Section P12: BIOTRANSFORMATION & DRUG TRANSPORTERS

P12.1 Differential interaction of enterolignans with the ovine ABCG2-mediated transport of danofloxacin
GRACIA MERINO, DAFNE GARCÍA-MATEOS, JON A. OTERO, MANUEL OLAZÁBAL-MORAN, ALBA M. GARCÍA-LINO & ANA I. ÁLVAREZ

P12.2 Role of the enterolignan enterodiol as an in vitro inhibitor of the transporter ABCG2/BCRP in ruminants using mitoxantrone accumulation assays
ALBA M. GARCÍA-LINO, SHEILA DIEZ-CASADO, DAFNE GARCÍA-MATEOS, INDIRA ÁLVAREZ-FERNÁNDEZ, ANA I. ÁLVAREZ & GRACIA MERINO

P12.3 In vitro transepithelial transport of the fluoroquinolone flumequine by the ruminant ABCG2 transporter
DAFNE GARCÍA-MATEOS, ALBA M. GARCÍA-LINO, INDIRA ÁLVAREZ-FERNÁNDEZ, ESTHER BLANCO-PANIAGUA, ANA I. ÁLVAREZ & GRACIA MERINO

P12.4 A preliminary investigation on the effects of quercetin on aflatoxin B1 (AFB1) toxicity and transport in an in vitro model of functional Caco-2 intestinal cells
SHIVA GHADIRI, LAURA SOLER-VASCO, LUCA DELLAFIORA, CHIARA DALL’ASTA, CARLO NEBBIA, FLAVIA GIROLAMI & ISABELLE OSWALD

P12.5 Metabolism and efflux of enrofloxacin in primary bovine mammary epithelial cells: a pilot study
ANELIYA MILANOVA, EKATERINA VACHKHOVA & NASKO VASILEV

P12.6 Effect of flavonoids on cytochrome P450 activity in porcine intestinal epithelial cells - in vitro interaction study
ORSOLYA FARKAS, ZITA KARANCSI, DÓRA KOVÁCS, BAKUMENKO LUBOV, GYÖRGY CSIKÓ & ORSOLYA PALÓCZ

P12.7 Determining mefloquine’s in vitro phase II conjugative hepatic metabolism using feline microsomes
AARON IZES, BENJAMIN KIMBLE, KONG LI, JACQUELINE NORRIS & MERRAN GOVENDIR

P12.8 Cytochrome P450 gene expression of porcine jejunal cells exposed to feed additives
ORSOLYA PALÓCZ & GYÖRGY CSIKÓ

P12.9 Examination of the interspecies differences in microsomal drug metabolism in chickens and rabbits
GYÖRGY CSIKÓ & ORSOLYA PALÓCZ

P12.10 Cytotoxicity and biotransformation of enrofloxacin in HepG2 cell culture
LIDIA RADKO, MALGORZATA GBYLIK-SIKORSKA, ANNA GAJDA, SYLWIA STYPUŁA-TREBAS & ANDRZEJ POSYNIAK

P12.11 Interaction of enrofloxacin and deoxynivalenol and effects on their biotransformation in HepG2 cells
LIDIA RADKO, MALGORZATA GBYLIK-SIKORSKA, ANGELIKA TKACZYK, ANNA GAJDA, SYLWIA STYPUŁA-TREBAS, PIOTR JEDZINIAK & ANDRZEJ POSYNIAK

Section P13: MODELLING & SIMULATION

P13.1 PBPK modelling of Collie plasma and brain concentrations as impacted by P-gp to explore loperamide induced CNS toxicity
DEVENDRA PADE, SIBYLLE NEUHOFF, BIPIN MISTRY, MASOUD JAMEI, MICHAEL J. MYERS & MARILYN N. MARTINEZ

P13.2 Predicting albumen/yolk distribution ratios of drug residues in eggs
G. JOHAN SCHEFFERLIE & PETER HERMAN

P13.3 Investigation of sparse clinical sampling in light of baseline oscillations and between-individual variability using pharmacokinetic/pharmacodynamic modelling
FELIX HELD, CARL EKSTRAND, JOHAN GABRIELSSON & MATS JIRSTRAND

P13.4 Physiologically based pharmacokinetic model for the prediction of quinocetone residues in food animals and extrapolation to mequindox and olaquindox
LINGLI HUANG, XUDONG ZHU, YAMEI XU, SHUYU XIE, YUANHU PAN, DONGMEI CHEN, ZHENLI LIU & ZONGHUI YUAN

P13.5 Measurement error modeling of tumor volume in a xenograft mouse model of non-small cell lung cancer
BENJAMIN K SCHNEIDER, KENNETH WANG, MARTIN FERNANDEZ-ZAPICO, SEBASTIEN BENZEKRY* & JONATHAN P MOCHEL

P13.6 Accounting for intra-species variability in drug exposure and residues with physiologically-based pharmacokinetic modeling
FEMKE J. TAVERNE, RONETTE GEHRING, B. MEIJER, DICK J.J. HEEDERIK, JOHAN W. MOUTON & NYNKE I. KRAMER

Poster session 5
Day 3: Tuesday, 26th June

Up to 9 posters from the Sections P14-P17 will be orally presented during the session 5 (Tuesday, Room C, 4:30 pm – 5:30 pm)

Evaluation Committee 5
Jonathan Elliott (Chairperson), Aneliya Milanova, Jean-Claude Desfontis, Linda Horspool, György Csico, Krystyna Okoniewska

Section P14: IMMUNOPHARMACOLOGY & BIOLOGICS

P14.1 Modulating effect of a new ester, 28-O-phosphatidylbetulin (DAPB), obtained from hen egg yolk lecithin on cellular and humoral immune response in mice. Comparison with betulin
BOŻENA OBMINSKA-MRUKOWICZ, ANGELIKA SYSAK, ALEKSANDRA PAWLAK, AGNIESZKA SUŚZKO-PAWŁOWSKA, MAGDALENA LIS & MARIANNA SZCZYPKA
P14.2 Histamine H2 receptor (H2R) agonist and a combination of H2R agonist and histamine H4 receptor (H4R) antagonist ameliorates imiquimod-induced psoriasis-like skin inflammation in mice
MANFRED KIETZMANN, KATHARINA WAHLE & KRISTINE ROSSBACH

P14.3 Potential biological activities of ethanolic extract of Cornus officinalis using various in vitro models of atopic dermatitis
JIN-YOON KIM, SEUNG-JIN LEE, NA-HYE PARK, ZI-EUM JONG, BIJUK TESFAYE BIRHANU, ABDULREHIM FIKRU MECHESO, NAILA BOBY, JI-YONG PARK & SEUNG-CHUN PARK

P14.4 In vitro studies on the effect of oclacitinib on canine CD4+ T cells – preliminary results
AGNIESZKA JASIECKA-MIKOŁAJCZYK, JERZY J. JAROSZEWSKI & TOMASZ MAŚLANKA

P14.5 Hawthorn procyanidin extract modulates primary humoral immune response in mice
MAGDALENA LIS, MARIANNA SZCZYPKA, AGNIESZKA SUSZKO-PAWŁOWSKA, BOŻENA OBMIŃSKA-MRUKOWICZ, ANNA SOKÓŁ-ŁĘTOWSKA & ALICJA KUCHARSKA

P14.6 Heat stress alters the gene expression of nutrient transporters along the chicken small intestine and dietary galacto-oligosaccharides are able to modulate this response
SOHEIL VARASTEH, SASKIA BRABER, ALETTA D. KRANEVELD, JOHAN GARSSEN & JOHANNA FINK-GREMMELS

P14.7 The phagocytic activity of blood monocytes and granulocytes after oral clomipramine or selegiline administration in mice
ANNA SOBIESZCZAŃSKA, MAGDALENA LIS, AGNIESZKA SUSZKO-PAWŁOWSKA & MARIANNA SZCZYPKA

P14.8 The development of a bacteriophage preparation intended to use in the treatment and prevention of the American and European foulbrood of honey bee
EWA JONCZYK-MATYSIAK, KINGA SWITALA-JELEN, DOMINIKA KULA, NATALIA BAGINSKA, NORBERT LODEJ, BEATA WEBER-DABROWSKA, KATARZYNA HODYRA-STEFANIAK, EWA POPIELA-PLEBAN, PAWEŁ MIGDAŁ, ADAM ROMAN & ANDRZEJ GORSKI

Section P15: PHARMACODYNAMICS

P15.1 Effects of natural antioxidants on methimazole-induced cytotoxicity in a feline kidney cell line (CFRK)
ALESSIA CANDELLONE, FLAVIA GIROLAMI, IMMAGOLATA CARFORA, CARLO NEBBIA, GIORGIA MEIÑERI, ROSANGELA ODORE & PAOLA BADINO

P15.2 TGF-β1 induced Epithelial-Mesenchymal Transition (EMT) and Mesenchymal-Epithelial Transition (MET) made changes in profile of CD24, CD44 and caspase-3 expression in A549, H23, H358 and H1299 lung cancer cell lines
SEONG-KWAN KIM, WEIPIA JUNQ, JEONG-MIN CHOI, KYUNG-HEE YOO, DA-HEE PARK & HO-CHUL SHIN

P15.3 CB1 receptor hippocampal expression in canine epilepsy
MARTA NOWAKOWSKA, DRAGINJA KOSTIC, FABIO GUALTIERI, JESSICA FREUNDT REVILLA, FREDERIKE ATTIG, WOLFGANG BAUMGÄRTNER, HEIDRUN POTSCHKA & ANDREA TIPOLD

Section P16: PAIN & INFLAMMATION

P16.1 Impact of different compounds on lidocaine permeation through equine skin
JESSICA MEISSNER, CONSTANTIN FREIHERR VON UND ZU BIBRA, NIKLAS SCHMAUCH & MANFRED KIETZMANN

P16.2 Doxycycline and meloxicam can treat neuroinflammation in rat brain
DEVRA COSKUN, BURAK DIK, EMRE BAHCIAN & AYŞE ER

P16.3 Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in cats
L. JAY STALLONS, WOLFGANG SEEWALD, MARK C. HEIT CÉLINE E. TOUTAIN, GABRIELE FRITON, STEPHEN B. KING & RAINER HELBIG

P16.4 Clinical safety of robenacoxib (Onsior™) in cats with chronic musculo-skeletal disorder or osteoarthritis
JONATHAN N. KING, CARYN THOMPSON, SOPHIE FORSTER, DEREK ADRIAN, STEPHEN KING, GABRIELE FRITON & B. DUNCAN X. LASCELLES
P16.5 Janus kinase inhibitors differ in their affinity to the TRPV1 receptor – implications for their use in itch and pain
LAURA SANABRIA-OJEDA, TOMOKI FUKUYAMA, DENIS FOURCHES & WOLFGANG BÄUMER

P16.6 The analgesic effects of carprofen in combination with buprenorphine (Vetergesic or Simbadol) in dogs undergoing ovariohysterectomy: a randomized, blinded, clinical trial
RYOTA WATANABE, BEATRIZ P MONTEIRO, MARINA C EVANGELISTA, AMÉLIE CASTONGUAY & PAULO V STEAGALL

P16.7 Thermal antinociception after buccal administration of a high-concentration formulation of buprenorphine (Simbadol) in conscious cats
GRAEME M DOODNAUGHT, BEATRIZ MONTEIRO, DANIEL EDGE & PAULO VM STEAGALL

P16.8 Cardiac side effects and electrocardiographic changes of the combination of pethidine with xylazine in horses
MARYAM POUYAN, SAEED OZMAIE, MEHDI SAKHA, AHMAD ASGHARI

P16.9 Maternal, amniotic and placental concentrations of propofol and dexmedetomidine after administration for elective caesarean section in the bitch
FEDERICA DI CESARE, ROBERTO VILLA, GIULIANO RAVASIO, LORENA LUCATELLO, ALESSANDRO PECILE, DEBORA GROPPETTI, PETRA CAGNARD

Section P17: REGULATORY AFFAIRS

P17.1 Meta-analysis to assess the validity of the International Residue Limits for the methylxanthines caffeine and theophylline in horseracing
ROBERT HERTZSCH & ANGELIKA RICHTER

P17.2 Strengthening of scientific excellence of the National Veterinary Research Institute in animal health and food chain safety
MIROSŁAW P. POLAK, JACEK KUZMAK, DARIUSZ WASYL, MALGORZATA OLEJNIK, KRZYSZTOF SMIETANKA & GRZEGORZ WOZNIAKOWSKI

P17.3 Regulatory challenges for cell based veterinary medicinal products in the EU
ANNEGRET WÜNSCH, REGINA WOLF & KLAUS HELLMANN

P17.4 Adverse drug reactions in patients admitted to the hospitalization area at the small animal clinic at the National University of Colombia
OSCAR J. MONTANA & CAMILO OROZCO